- Home
- FXNC vs VCRE Comparison
FXNC vs VCRE Comparison
Compare FXNC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FXNC | VCRE |
|---|---|---|
| Founded | 1907 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.4M | 316.4M |
| IPO Year | 2012 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FXNC | VCRE |
|---|---|---|
| Price | $29.40 | $9.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.8K | 12.0K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $2.93 | N/A |
| P/E Ratio | $26.03 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $21.59 | $10.03 |
| 52 Week High | $33.24 | $13.15 |
Technical Indicators
Market Signals| Indicator | FXNC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.72 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $13.00 |
| Average True Range (ATR) | 0.00 | 0.55 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 9.43 |
Price Performance
Historical ComparisonAbout FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.